These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35695781)

  • 41. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.
    Ali M; Raslan M; Ciebiera M; Zaręba K; Al-Hendy A
    Expert Opin Drug Saf; 2022 Apr; 21(4):477-486. PubMed ID: 34612122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
    Syed YY
    Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elagolix for endometriosis: all that glitters is not gold.
    Vercellini P; Viganò P; Barbara G; Buggio L; Somigliana E;
    Hum Reprod; 2019 Feb; 34(2):193-199. PubMed ID: 30551159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix.
    Chwalisz K
    F S Rep; 2023 Jun; 4(2 Suppl):65-72. PubMed ID: 37223767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life.
    Watts NB; Binkley N; Owens CD; Al-Hendy A; Puscheck EE; Shebley M; Schlaff WD; Simon JA
    J Womens Health (Larchmt); 2021 Oct; 30(10):1416-1430. PubMed ID: 34435897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
    DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
    Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
    Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
    Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women.
    Feldman RA; Chiu YL; Klein CE; Ng J
    Clin Pharmacokinet; 2021 Aug; 60(8):1003-1013. PubMed ID: 33748934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.
    Winzenborg I; Nader A; Polepally AR; Liu M; Degner J; Klein CE; Mostafa NM; Noertersheuser P; Ng J
    Clin Pharmacokinet; 2018 Oct; 57(10):1295-1306. PubMed ID: 29476499
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Virtual Bioequivalence Assessment of Elagolix Formulations Using Physiologically Based Pharmacokinetic Modeling.
    Mukherjee D; Chen MJ; Shao X; Ju TR; Shebley M; Marroum P
    AAPS J; 2023 Mar; 25(3):30. PubMed ID: 36949256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fracture Risk Indices From DXA-Based Finite Element Analysis Predict Incident Fractures Independently From FRAX: The Manitoba BMD Registry.
    Leslie WD; Luo Y; Yang S; Goertzen AL; Ahmed S; Delubac I; Lix LM
    J Clin Densitom; 2019; 22(3):338-345. PubMed ID: 30852033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
    Morris EP; Rymer J; Robinson J; Fogelman I
    Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients.
    Abrao MS; Surrey E; Gordon K; Snabes MC; Wang H; Ijacu H; Taylor HS
    BMC Womens Health; 2021 Jun; 21(1):246. PubMed ID: 34134684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women.
    Delmas PD; Confavreux E; Garnero P; Fardellone P; de Vernejoul MC; Cormier C; Arce JC
    Osteoporos Int; 2000; 11(2):177-87. PubMed ID: 10793878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Digital X-ray radiogrammetry in the study of osteoporotic fractures: Comparison to dual energy X-ray absorptiometry and FRAX.
    Kälvesten J; Lui LY; Brismar T; Cummings S
    Bone; 2016 May; 86():30-5. PubMed ID: 26921822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.
    Donaldson MG; Palermo L; Ensrud KE; Hochberg MC; Schousboe JT; Cummings SR
    J Bone Miner Res; 2012 Aug; 27(8):1804-10. PubMed ID: 22492479
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.
    Ng J; Duan WR; Marbury T; Schmidt JM; Klein CE
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1053-1061. PubMed ID: 30570832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.